Intellective Bio's Operational Installed capacity Surpasses 100,000 Litres-Newsroom

Lines 9 and 10 of Intellective Bio (Suzhou) Co., Ltd. are scheduled to commence operations in September 2025. This expansion will significantly increase Intellective Bio's drug substance capacity, accelerating and empowering global innovative pharmaceutical companies in the R&D process of diverse biologics.

The previously commissioned Lines 7 and 8 in 2023 comprise two cell-culture lines and two protein-purification lines. With production scales ranging from 2000 litres to 6000 litres, they offer flexible configuration to meet clients' full-process requirements.

Core Highlights

Integrated Safety & Intelligence for Excellent Operations

• The Changshu site utilises an automated material handling system, enabling precise sample delivery from multiple production lines to the IPC testing centre within 30 seconds. This minimises transfer risks and ensures data timeliness.

• The Emerson DeltaV™ Distributed Control System serves as the automation platform for drug substance production, enabling "centralised monitoring and decentralised control" of upstream and downstream processes. It facilitates independent process control, ensuring that anomalies in a single unit operation do not impact overall production, thereby greatly enhancing system reliability and safety and enabling intelligent production management.

• The implementation of an online buffer preparation system (CIP/SIP) allows for automatic and precise buffer preparation according to preset recipes, with real-time on-demand replenishment. This significantly saves storage space, reduces manual intervention and handling risks, and improves overall production efficiency and batch-to-batch consistency.